The Covid-19 pandemic that has swept the globe has led to a massive search for a drug with which to combat this deadly virus, yet despite many pharmaceutical companies continuing to pour their resources into a cure for this virus, the development of prophylactic vaccines for Covid-19 appears to be lagging.
According to GlobalData’s Pharma Intelligence Center Pipeline Database and the Coronavirus Disease 2019 (Covid-19) dashboard, there are, as of 23 April, 80 therapeutic drugs in Phases I, II, and III that may be able to treat Covid-19, but only nine prophylactic vaccine drugs in Phases I and II, indicating that while a possible cure for Covid-19 may be imminent, a prophylactic vaccine to combat the pandemic may need more time to come to fruition.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Click here to read the full article.
